A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT

We report a single-center phase I/II trial exploring the combination of everolimus (EVE) and mycophenolate mofetil (MMF) as calcineurin inhibitor (CNI)-free GVHD prophylaxis for 24 patients with hematologic malignancies and indication for allogeneic HCT after a high dose or reduced-intensity ablativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Henning, Blümel-Lehmann, Jacqueline, Ihorst, Gabriele, Bertz, Hartmut, Wäsch, Ralph, Zeiser, Robert, Finke, Jürgen, Marks, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285343/
https://www.ncbi.nlm.nih.gov/pubmed/33755792
http://dx.doi.org/10.1007/s00277-021-04487-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285343/
https://www.ncbi.nlm.nih.gov/pubmed/33755792
http://dx.doi.org/10.1007/s00277-021-04487-y

Ejemplares similares